Malignant mixed mesodermal tumor of the ovary treated with a cisplatin-irinotecan combination: case report

Mixed Mullerian Tumor; Irinotecan

[1] Krishnan E., Coleman R. E.: "Malignant mixed mullerian tumours of gynaecological origin: chemosensitive but aggressive tumours". Clinical Oncology (Royal College of Radiologists), 1998, 10(4), 246.

[2] Pfeiffer P. et al.: "Malignant mixed mullerian tumors of the ovary. Report of 13 cases". Acta Obstetricia et Gynecologica Scandinavica, 1991, 70(1), 79.

[3] Verschraegen C.F., Edwards C. L., Fox H.: "Present knowledge of gynecologic sarcoma management". Hematology Oncology Clinics of North America, I 999, 13(1), 211.

[4] Silverberg S. G. et al.: "Carcinosarcoma (malignant mixed mesodermal tumor) of the uterus. A Gynecologic Oncology Group pathologic study of 203 cases". International Journal of Gynecological Pathology, 1990, 9(1), 1.

[5] Rose P. G., Rodriguez M., Abdul-Karim F. W.: "Malignant mixed mullerian tumor of the female peritoneum: treatment and outcome of three cases". Gynecologic Oncology, 1997, 65(3), 523.

[6] Olah K.S., Dunn J. A., Gee H.: "Leiomyosarcomas have a poorer prognosis than mixed mesodermal tumours when adjusting for known prognostic factors: the result of a retrospective study of 423 cases of uterine sarcoma". British Journal of Obstetrics & Gynaecology, 1992, 99(7), 590.

[7] Resnik E. et al.: "A phase II study of etoposide, cisplatin, and doxorubicin chemotherapy in mixed mullerian tumors (MMT) of the uterus". Gynecologic Oncology, 1995, 56(3), 370.

[8] Kohorn E. I. et al.: "Adjuvant therapy in mixed mullerian tumors of the uterus". Gynecologic Oncology, 1986, 23(2), 212.

[9] Knocke T. H. et al.: "Results of primary and adjuvant radiotherapy in the treatment of mixed Mullerian tumors of the corpus uteri" Gynecologic Oncology, 1999, 73(3), 389.

[10] Gonzalez-Bosquet E. et al.: "Uterine sarcoma: a clinicopathological study of 93 cases". European Journal of Gynaecological Oncology, 1997, 18(3), 192.

[11] Major F. J. et al.: "Prognostic factors in early-stage uterine sarcoma. A Gynecologic Oncology Group study". Cancer, 1993, 71 (4 Suppl), 1702.

[12] Sutton G. P. et al.: "A phase II trial of ifosfamide and mesna in patients with advanced or recurrent mixed mesodermal tumors of the ovary previously treated with platinum-based chemotherapy: a Gynecologic Oncology Group study". Gynecologic Oncology, 1994, 53(1), 24.

[13] Thigpen J. T. et al.: "Phase II trial of cisplatin in the treatment of patients with advanced or recurrent mixed mesodermal sarcomas of the uterus: a Gynecologic Oncology Group Study". Cancer Treatment Reports, I 986, 70(2), 271.

[14] Thigpen J. T. et al.: "Phase II trial of cisplatin as first-line chemotherapy in patients with advanced or recurrent uterine sarcomas: a Gynecologic Oncology Group study [see comments]'' Journal of Clinical Oncology, 1991, 9(11), 1962.

[15] Grosh W. W. et al.: "Malignant mixed mesodermal tumors of the uterus and ovary treated with cisplatin-based combination chemotherapy". Gynecologic Oncology, 1986, 25(3), 334.

[16] Baker T. R. et al.: "Prospective trial of cisplatin, adriamycin, and dacarbazine in metastatic mixed mesodermal sarcomas of the uterus and ovary [published erratum appears in Am. J. Clin. Oncol., 1991 Oct., 14(5), 455]. American Journal of Clinical Oncology, 1991, 14(3), 246.

[17] Andersen W. A. et al.: "Platinum-based combination chemotherapy for malignant mixed mesodermal tumors of the ovary". Gynecologic Oncology, 1989, 32(3), 319.

[18] Eltabbakh G. H., Yadav R.: "Good response of malignant mixed mullerian tumor of the ovary to paclitaxel and cisplatin chemotherapy". European Journal of Gynaecological Oncology, 1999, 20(5-6), 355.

[19] Slayton R. E. et al.: "Phase II trial of etoposide in the management of advanced or recurrent mixed mesodermal sarcomas of the uterus: a Gynecologic Oncology Group Study". Cancer Treat Rep., 1987, 71(6), 661.

[20] Clement P. B., Oliva E., Young R. H.: "Mullerian adenosarcoma of the uterine corpus associated with tamoxifen therapy: a report of six cases and a review of tamoxifen-associated endometrial lesions". International Journal,)fGynecological Pathology, 1996, 15(3), 222.

[21] Olah K. S.: "Ut erine carcinosarcoma in association with tamoxifen therapy [letter; comment]". British Journal of Obstetrics &Gynaecology, 1997, 104(12), 1420.

[22] Muthuphei M. N., Maluleke H. J.: "Malignant mixed mullerian tumours of the body of the uterus: a clinicopathological study of 20 cases". Central African Journal of Medicine, 1998, 44(2), 45.

[23] Thigpen J. T. et al.: "Phase II trial of piperazinedione in patients with advanced or recurrent uterine sarcoma. A Gynecologic Oncology Group study". American Journal of Clinical Oncology, 1985, 8(5), 350.

[24] Muss H. B. et al.: "Mitoxantrone in the treatment of advanced uterine sarcoma. A phase II trial of the Gynecologic Oncology Group". American Journal of Clinical Oncology, 1990, 13(1), 32.

[25] Muss H. B. et al.:'Treatment of recurrent or advanced uterine sarcoma. A randomized trial of doxorubicin versus doxorubicin and cyclophosphamide (a phase III trial of the Gynecologic Oncology Group)". Cancer, 1985, 55(8), 1648.

[26] Resnik E. et al.: "Malignant uterine smooth muscle tumors: role of etoposide, cisplatin, and doxorubicin (EPA) chemotherapy". Journal of Surgical Oncology, 1996, 63(3), 145.

[27] Kavanagh J. J., Verschraegen C. F., Kudelka A. P.: "lrinotecan in cervical cancer. [Review]". Oncology, I 998, 12(8 Suppl 6), 94.

[28] Haluska P.. Rubin E., Verschraegen C.: "Topoisomerase-I inhibi－tors in gynecologic tumors". Hematology/Oncology C linics of North America, 1999, 13(1).

[29] Sugiyama T. et al.: "Irinotecan (CPT-11) combined with cisplatm in patients with refractory or recurrent ovarian cancer". Cancer Letters, 1998, 128(2), 211.

[30] Sugiyama T. et al.: "Combination therapy with irinotecan and cisplatin as neoadjuvant chemotherapy in locally advanced cervical cancer". British Journal of Cancer, 1999, 81(1), 95.

[31] Gerrits C .J. et al.: "Topoisomerase I inhibitors: the relevance of prolonged exposure for present clinical development". Br. J Cancer, 1997, 76(7), 952.